Patents by Inventor Christopher W.L. CHIU

Christopher W.L. CHIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20240301078
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Application
    Filed: November 2, 2023
    Publication date: September 12, 2024
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20240034812
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Application
    Filed: September 10, 2021
    Publication date: February 1, 2024
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA
    Publication number: 20230357440
    Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
    Type: Application
    Filed: September 10, 2021
    Publication date: November 9, 2023
    Inventors: Brian ELLIOTT, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA
    Publication number: 20230312757
    Abstract: Provided are methods of clinical treatment of chromic lymphoblastic leukemia (CLL) inhuman subjects using a bispecific-antibody which binds to CD3 and CD20.
    Type: Application
    Filed: September 10, 2021
    Publication date: October 5, 2023
    Inventors: Brian ELLIOTT, Jenny J. CHEN, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BRElJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20220119544
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Application
    Filed: December 21, 2021
    Publication date: April 21, 2022
    Inventors: Brian Elliott, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA
    Publication number: 20220112287
    Abstract: Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Brian Elliott, Jenny Jianlin CHEN, Tahamtan AHMADI, Christopher W.L. CHIU, Esther C.W. BREIJ, Ida HIEMSTRA, Maria N. JURE-KUNKEL